NCT03515824: Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

NCT03515824
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: MBC patients will not be eligible for expansion phase
Exclusions: Clinically active central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT03515824

Comments are closed.

Up ↑